Prostacyclin in the intensive care setting

Pediatric Critical Care Medicine

Volumn 11, Issue SUPPL. 2, 2010, Pages

  Dunbar, D ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Congenital heart disease; Critical care; Epoprostenol; Iloprost; Pulmonary arterial hypertension; Treprostinil

Indexed keywords

BOSENTAN; ILOPROST; NITRIC OXIDE; PROSTACYCLIN; SILDENAFIL; UNIPROST;

BIOEQUIVALENCE; CHILD CARE; CONFERENCE PAPER; DIARRHEA; DISEASE EXACERBATION; DRUG COST; DRUG DOSE TITRATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; FLUSHING; HUMAN; HYPOTENSION; INTENSIVE CARE; INTUBATION; JAW DISEASE; LUNG PERFUSION; MUSCULOSKELETAL PAIN; NAUSEA; NEBULIZATION; PAIN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SIDE EFFECT; UNSPECIFIED SIDE EFFECT;

EID: 77949465630     PISSN: 15297535     EISSN: None     Source Type: Journal    
DOI: 10.1097/PCC.0b013e3181d10845     Document Type: Conference Paper

References (52)

1. Vane J, Corin RE: Prostacyclin: A vascular mediator. Eur J Vasc Endovasc Surg 2003; 26:571-578
2. Gomberg-Maitland M, Olschewski H: Prostacyclin therapies for the treatment of pulmonary arterial hypertension. Eur Respir J 2008; 31:891-901
3. O'Grady J, Warrington S, Moti MJ, et al: Effects of intravenous infusion of prostacyclin (PGI2) in man. Prostaglandins 1980; 19: 319-332
4. Higenbottam T, Wheeldon D, Wells F, et al: Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin). Lancet 1984; 1:1046-1047
5. Badesch DB, Abman SH, Simonneau G, et al: Medical therapy for pulmonary arterial hypertension: Updated ACCP evidence-based clinical practice guidelines. Chest 2007; 131: 1917-1928
6. Moncada S, Gryglewski R, Bunting S, et al: An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976; 263:663-665
7. Rashid N, Morin FC 3rd, Swartz DD, et al: Effects of prostacyclin and milrinone on pulmonary hemodynamics in newborn lambs with persistent pulmonary hypertension induced by ductal ligation. Pediatr Res 2006; 60:624-629
8. Christman BW, McPherson CD, Newman JH, et al: An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992; 327:70-75
9. Adatia I, Barrow SE, Stratton PD, et al: Thromboxane A2 and prostacyclin biosynthesis in children and adolescents with pulmonary vascular disease. Circulation 1993; 88: 2117-2122
10. Tuder RM, Cool CD, Geraci MW, et al: Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 1999; 159:1925-1932
11. Barst RJ, Rubin LJ, Long WA, et al: A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 334:296-302
12. Barst RJ, Maislin G, Fishman AP: Vasodilator therapy for primary pulmonary hypertension in children. Circulation 1999; 99:1197-1208
13. Yung D, Widlitz AC, Rosenzweig EB, et al: Outcomes in children with idiopathic pulmonary arterial hypertension. Circulation 2004; 110:660-665
14. Ivy DD, Doran A, Claussen L, et al: Weaning and discontinuation of epoprostenol in children with idiopathic pulmonary arterial hypertension receiving concomitant bosentan. Am J Cardiol 2004; 93:943-946
15. Lammers AE, Hislop AA, Flynn Y, et al: Epoprostenol treatment in children with severe pulmonary hypertension. Heart 2007; 93:739-743
16. McLaughlin VV, Shillington A, Rich S: Survival in primary pulmonary hypertension: The impact of epoprostenol therapy. Circulation 2002; 106:1477-1482
17. Sitbon OHM, Nunes H, Parent F, et al: Longterm intravenous epoprostenol infusion in primary pulmonary hypertension: Prognostic factors and survival. J Am Coll Cardiol 2002; 40:780-788
18. Rubin LJ, Mendoza J, Hood M, et al: Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med 1990; 112:485-491
19. Barst RJ, Rubin LJ, McGoon MD, et al: Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 1994; 121: 409-415
20. Rosenzweig EB, Kerstein D, Barst RJ: Longterm prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation 1999; 99:1858-1865
21. Humbert M, Barst RJ, Robbins IM, et al: Combination of bosentan with poprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 2004; 24: 353-359
22. Simonneau G, Rubin LJ, Galie N, et al: Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: A randomized trial. Ann Intern Med 2008; 149:521-530
23. Max M, Rossaint R: Inhaled prostacyclin in the treatment of pulmonary hypertension. Eur J Pediatr 1999; 158 Suppl 1:S23-S26
24. Katz SL, Adatia I, Louca E, et al: Nebulized therapies for childhood pulmonary hypertension: An in vitro model. Pediatr Pulmonol 2006; 41:666-673
25. Kelly LK, Porta NF, Goodman DM, et al: Inhaled prostacyclin for term infants with persistent pulmonary hypertension refractory to inhaled nitric oxide. J Pediatr 2002; 141:830-832
26. Simonneau G, Barst RJ, Galie N, et al: Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: A doubleblind randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165: 800-804
27. Barst RJ, Galie N, Naeije R, et al: Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J 2006; 28:1195-1203
28. Laliberte K, Arneson C, Jeffs R, et al: Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin) administered by the intravenous and subcutaneous route to normal volunteers. J Cardiovasc Pharmacol 2004; 44:209-214
29. Widlitz AC, McDevitt S, Ward GR, et al: Practical aspects of continuous intravenous treprostinil therapy. Crit Care Nurse 2007; 27:41- 42, 44-45, 47-50; quiz, 51
30. Ivy DD, Claussen L, Doran A: Transition of stable pediatric patients with pulmonary arterial hypertension from intravenous epoprostenol to intravenous treprostinil. Am J Cardiol 2007; 99:696-698
31. Doran A, Harris S, Goetz B: Advances in prostanoid infusion therapy for pulmonary arterial hypertension. J Infus Nurs 2008; 31: 336-345
32. Centers for Disease Control and Prevention (CDC): Bloodstream infections among patients treated with intravenous epoprostenol or intravenous treprostinil for pulmonary arterial hypertension-seven sites, United States, 2003-2006. MMWR Morb Mortal Wkly Rep 2007; 56:170-172
33. Doran AK, Ivy DD, Barst RJ, et al: Guidelines for the prevention of central venous catheter- related blood stream infections with prostanoid therapy for pulmonary arterial hypertension. Int J Clin Pract Suppl 2008; 5-9
34. Tapson VF, Gomberg-Maitland M, McLaughlin VV, et al: Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: A prospective, multicenter, open-label, 12-week trial. Chest 2006; 129:683-688
35. Channick RN, Olschewski H, Seeger W, et al: Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension. J Am Coll Cardiol 2006; 48:1433-1437
36. Voswinckel R, Enke B, Reichenberger F, et al: Favorable effects of inhaled treprostinil in severe pulmonary hypertension: Results from randomized controlled pilot studies. J Am Coll Cardiol 2006; 48:1672-1681
37. Voswinckel R, Reichenberger F, Enke B, et al: Acute effects of the combination of sildenafil and inhaled treprostinil on haemodynamics and gas exchange in pulmonary hypertension. Pulm Pharmacol Ther 2008; 21: 824-832
38. Voswinckel R, Reichenberger F, Gall H, et al: Metered dose inhaler delivery of treprostinil for the treatment of pulmonary hypertension. Pulm Pharmacol Ther 2009; 22:50-56
39. Hoeper MM, Schwarze M, Ehlerding S, et al: Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med 2000; 342:1866-1870
40. Ivy DD, Doran AK, Smith KJ, et al: Shortand long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension. J Am Coll Cardiol 2008; 51: 161-169
41. McLaughlin VV, Oudiz RJ, Frost A, et al: Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 2006; 174:1257-1263
42. Olschewski H, Simonneau G, Galie N, et al: Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347:322-329
43. Ewert R, Opitz CF, Wensel R, et al: Continuous intravenous iloprost to revert treatment failure of first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. Clin Res Cardiol 2007; 96:211-217
44. Hallioglu O, Dilber E, Celiker A: Comparison of acute hemodynamic effects of aerosolized and intravenous iloprost in secondary pulmonary hypertension in children with congenital heart disease. Am J Cardiol 2003; 92:1007-1009
45. Hoeper MM, Spiekerkoetter E, Westerkamp V, et al: Intravenous iloprost for treatment failure of aerosolised iloprost in pulmonary arterial hypertension. Eur Respir J 2002; 20: 339-343
46. Rimensberger PC, Spahr-Schopfer I, Berner M, et al: Inhaled nitric oxide versus aerosolized iloprost in secondary pulmonary hypertension in children with congenital heart disease: Vasodilator capacity and cellular mechanisms. Circulation 2001; 103:544-548
47. Winterhalter M, Simon A, Fischer S, et al. Comparison of inhaled iloprost and nitric oxide in patients with pulmonary hypertension during weaning from cardiopulmonary bypass in cardiac surgery: A prospective randomized trial. J Cardiothorac Vasc Anesth 2008; 22:406-413
48. Limsuwan A, Wanitkul S, Khosithset A, et al: Aerosolized iloprost for postoperative pulmonary hypertensive crisis in children with congenital heart disease. Int J Cardiol 2008; 129: 333-338
49. Galie N, Humbert M, Vachiery JL, et al: Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: A randomized, doubleblind, placebo-controlled trial. J Am Coll Cardiol 2002; 39:1496-1502
50. Badesch DB, McLaughlin VV, Delcroix M, et al: Prostanoid therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43: 56S-61S
51. Barst RJ, McGoon M, McLaughlin V, et al: Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003; 41: 2119-2125
52. Kermode J, Butt W, Shann F: Comparison between prostaglandin E1 and epoprostenol (prostacyclin) in infants after heart surgery. Br Heart J 1991; 66:175-178